These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 23414588

  • 21. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [Abstract] [Full Text] [Related]

  • 22. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B.
    Cancer; 2012 Apr 15; 118(8):1982-8. PubMed ID: 21887681
    [Abstract] [Full Text] [Related]

  • 23. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
    Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ.
    J Clin Oncol; 2010 Jul 20; 28(21):3422-8. PubMed ID: 20530280
    [Abstract] [Full Text] [Related]

  • 24. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).
    Azim HA, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M.
    Breast Cancer Res Treat; 2012 May 20; 133(1):387-91. PubMed ID: 22367645
    [Abstract] [Full Text] [Related]

  • 25. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
    Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 20; 27(36):6129-34. PubMed ID: 19917839
    [Abstract] [Full Text] [Related]

  • 26. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M.
    Clin Breast Cancer; 2008 Aug 20; 8(4):324-33. PubMed ID: 18757259
    [Abstract] [Full Text] [Related]

  • 27. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators.
    N Engl J Med; 2006 Feb 23; 354(8):809-20. PubMed ID: 16495393
    [Abstract] [Full Text] [Related]

  • 28. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
    Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ.
    J Clin Oncol; 2007 Sep 01; 25(25):3859-65. PubMed ID: 17646669
    [Abstract] [Full Text] [Related]

  • 29. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.
    J Clin Oncol; 2013 May 10; 31(14):1719-25. PubMed ID: 23569311
    [Abstract] [Full Text] [Related]

  • 30. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
    Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM, TEACH investigators.
    Lancet Oncol; 2013 Jan 10; 14(1):88-96. PubMed ID: 23234763
    [Abstract] [Full Text] [Related]

  • 31. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
    Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P, Crinò L.
    Oncologist; 2007 Jul 10; 12(7):766-73. PubMed ID: 17673608
    [Abstract] [Full Text] [Related]

  • 32. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C.
    Lancet Oncol; 2012 Sep 10; 13(9):869-78. PubMed ID: 22884505
    [Abstract] [Full Text] [Related]

  • 33. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL.
    J Clin Oncol; 2009 Dec 01; 27(34):5685-92. PubMed ID: 19884557
    [Abstract] [Full Text] [Related]

  • 34. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
    Bonifazi M, Franchi M, Rossi M, Zambelli A, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C, Negri E.
    Breast; 2014 Oct 01; 23(5):573-8. PubMed ID: 24934637
    [Abstract] [Full Text] [Related]

  • 35. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
    Montagna E, Cancello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M.
    Cancer Chemother Pharmacol; 2009 Jan 01; 63(2):275-80. PubMed ID: 18379783
    [Abstract] [Full Text] [Related]

  • 36. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
    Palmieri C, Shah D, Krell J, Gojis O, Hogben K, Riddle P, Ahmad R, Tat T, Fox K, Porter A, Mahmoud S, Kirschke S, Shousha S, Gudi M, Coombes RC, Leonard R, Cleator S.
    Clin Breast Cancer; 2011 Apr 01; 11(2):93-102. PubMed ID: 21569995
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA.
    Cancer; 2007 Aug 01; 110(3):489-98. PubMed ID: 17592827
    [Abstract] [Full Text] [Related]

  • 38. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S, Di Lauro L, Sergi D, Foggi P, Perri P, Tirelli C, Mottolese M, Fattoruso SI, Lopez M.
    Clin Ter; 2008 Aug 01; 159(6):449-52. PubMed ID: 19169607
    [Abstract] [Full Text] [Related]

  • 39. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F, Colin X, Arveux P, Coudert B, Misset JL.
    Bull Cancer; 2007 Jul 01; 94(7):711-20. PubMed ID: 17723955
    [Abstract] [Full Text] [Related]

  • 40. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
    Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S.
    Onkologie; 2013 Jul 01; 36(10):554-8. PubMed ID: 24107908
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.